tiprankstipranks
Trending News
More News >
Virax Biolabs Group Ltd. Class A (VRAX)
:VRAX
US Market
Advertisement

Virax Biolabs Group Ltd. Class A (VRAX) Stock Statistics & Valuation Metrics

Compare
108 Followers

Total Valuation

Virax Biolabs Group Ltd. Class A has a market cap or net worth of ―. The enterprise value is -$74.44K.
Market Cap
Enterprise Value-$74.44K

Share Statistics

Virax Biolabs Group Ltd. Class A has 4,341,956 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,341,956
Owned by Insiders
Owned by Institutions

Financial Efficiency

Virax Biolabs Group Ltd. Class A’s return on equity (ROE) is -1.06 and return on invested capital (ROIC) is -103.22%.
Return on Equity (ROE)-1.06
Return on Assets (ROA)-0.94
Return on Invested Capital (ROIC)-103.22%
Return on Capital Employed (ROCE)-1.07
Revenue Per Employee372.41
Profits Per Employee-356.90K
Employee Count17
Asset Turnover<0.01
Inventory Turnover0.63

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio0.48
Price to Fair Value0.00
Price to FCF-0.71
Price to Operating Cash Flow-0.59
PEG Ratio-0.02

Income Statement

In the last 12 months, Virax Biolabs Group Ltd. Class A had revenue of 6.33K and earned -6.06M in profits. Earnings per share was -1.96.
Revenue6.33K
Gross Profit-53.07K
Operating Income-6.16M
Pretax Income-6.20M
Net Income-6.06M
EBITDA-5.80M
Earnings Per Share (EPS)-1.96

Cash Flow

In the last 12 months, operating cash flow was -4.71M and capital expenditures -707.92K, giving a free cash flow of -5.42M billion.
Operating Cash Flow-4.71M
Free Cash Flow-5.42M
Free Cash Flow per Share-1.25

Dividends & Yields

Virax Biolabs Group Ltd. Class A pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.29
52-Week Price Change-12.82%
50-Day Moving Average0.94
200-Day Moving Average1.50
Relative Strength Index (RSI)59.49
Average Volume (3m)89.25K

Important Dates

Virax Biolabs Group Ltd. Class A upcoming earnings date is ―, ―.
Last Earnings Date
Next Earnings Date
Ex-Dividend Date

Financial Position

Virax Biolabs Group Ltd. Class A as a current ratio of 7.27, with Debt / Equity ratio of 6.62%
Current Ratio7.27
Quick Ratio7.13
Debt to Market Cap0.00
Net Debt to EBITDA0.66
Interest Coverage Ratio-105.93

Taxes

In the past 12 months, Virax Biolabs Group Ltd. Class A has paid -136.66K in taxes.
Income Tax-136.66K
Effective Tax Rate0.02

Enterprise Valuation

Virax Biolabs Group Ltd. Class A EV to EBITDA ratio is 0.66, with an EV/FCF ratio of 0.75.
EV to Sales-608.43
EV to EBITDA0.66
EV to Free Cash Flow0.75
EV to Operating Cash Flow0.84

Balance Sheet

Virax Biolabs Group Ltd. Class A has $7.38M in cash and marketable securities with $603.20K in debt, giving a net cash position of -$6.78M billion.
Cash & Marketable Securities$7.38M
Total Debt$603.20K
Net Cash-$6.78M
Net Cash Per Share-$1.56
Tangible Book Value Per Share$0.00

Margins

Gross margin is 39.59%, with operating margin of -97344.76%, and net profit margin of -95739.17%.
Gross Margin39.59%
Operating Margin-97344.76%
Pretax Margin-97992.31%
Net Profit Margin-95739.17%
EBITDA Margin-91649.46%
EBIT Margin-97073.35%

Analyst Forecast

The average price target for Virax Biolabs Group Ltd. Class A is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.00
Price Target Upside194.12% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart ScoreN/A
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis